Biotech Knockoffs Lure Novartis

Biotech Knockoffs Lure Novartis
“A big pharma player is expanding its generics business. Expect others to follow
The divide between those making brand-name drugs and those producing generics is about to become a bit less clear. “


Leave a Reply

Your email address will not be published. Required fields are marked *